Tamoxifen induced cardiac damage via the IL-6/p-STAT3/PGC-1α pathway
International Immunopharmacology · 2023-12 · 125 · 110978
DOI: 10.1016/j.intimp.2023.110978 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023-12. Verfasst von Tingting Meng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Research Center of Translational Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Interleukin-6, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Shandong Province, Shandong First Medical University.
Abstract (Originalsprache)
Tamoxifen (TAM) is an effective anticancer drug for breast and ovarian cancer. However, increased risk of cardiotoxicity is a long-term clinical problem associated with TAM, while the underlying mechanisms remain unclear. Here, we performed experiments in cardiomyocytes and tumor-bearing or nontumor-bearing mice, and demonstrated that TAM induced cardiac injury via the IL-6/p-STAT3/PGC-1α/IL-6 feedback loop, which is responsible for reactive oxygen species (ROS) accumulation. Compared with non-tumor bearing mice, tumor-bearing mice showed stronger cardiac toxicity after TAM injection, although there was no significant difference. In vitro experiments demonstrated STAT3 phosphorylation inhibitor can increase PGC-1α expression and protect cardiomyocyte via decreasing ROS. Since tumor has higher STAT3 phosphorylation and IL-6 expression level, our research results indicated combining TAM and STAT3 inhibitor might be an effective treatment strategy which can provide both tumor killing and cardioprotective function. Further in vivo research is needed to fully elucidate the effect and mechanisms of the combination therapy of TAM and STAT3 inhibitor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Center of Translational Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
- Jinan Central Hospital, Jinan, Shandong, China.
- Research Center of Translational Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China; Research Center of Translational Medicine, Jinan Central Hospital, Shandong University…
- Research Center of Translational Medicine, Jinan Central Hospital, Weifang Medical University, Weifang, China.
- Laboratory Animal Center, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
- Research Center of Translational Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. Electronic address: gttstg@163.com.
Förderung
- Natural Science Foundation of Shandong Province
- Shandong First Medical University
Zitieren
APA
Meng, T., Zhang, D., Zhang, Y., Tian, P., Chen, J., Liu, A., Li, Y., Song, C., Zheng, Y., & Su, G. (2023). Tamoxifen induced cardiac damage via the IL-6/p-STAT3/PGC-1α pathway. International Immunopharmacology, 125, 110978. https://doi.org/10.1016/j.intimp.2023.110978
Vancouver
Meng T, Zhang D, Zhang Y, Tian P, Chen J, Liu A, et al. Tamoxifen induced cardiac damage via the IL-6/p-STAT3/PGC-1α pathway. International Immunopharmacology. 2023;125:110978. doi:10.1016/j.intimp.2023.110978
BibTeX
@article{Meng2023,
author = {Meng, Tingting and Zhang, Dan and Zhang, Yu and Tian, Peng and Chen, Jianlin and Liu, Anbang and Li, Ying and Song, Chunhong and Zheng, Yan and Su, Guohai},
title = {Tamoxifen induced cardiac damage via the IL-6/p-STAT3/PGC-1α pathway},
journal = {International Immunopharmacology},
year = {2023},
volume = {125},
pages = {110978},
doi = {10.1016/j.intimp.2023.110978}
}
EUVIMED